Upstream Bio director granted 17,096 stock options
Upstream Bio, Inc. director Harold Edward Fleming reported a grant of stock options covering 17,096 shares of common stock, with an exercise price of $6.69 per share and expiration on June 8, 2036.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Upstream Bio, Inc. director Harold Edward Fleming reported a grant of stock options covering 17,096 shares of common stock, with an exercise price of $6.69 per share and expiration on June 8, 2036. The options vest in full on June 9, 2027 or the next annual stockholder meeting and are held for the benefit of Enavate Sciences, LP, with Mr. Fleming disclaiming beneficial ownership.
Insider Trade Summary
Grant/Award: 17,096 shares
Grant/Award
1 txn
Insider
Fleming Harold Edward
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 17,096 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 17,096 contracts (Direct)
Holdings Before and After:
Stock Option (Right to Buy), 0 to 17,096 contracts (Direct)
Footnotes (2)
- F1. The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
- F2. Mr. Fleming has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Issuer's board of directors. As such, Mr. Fleming disclaims beneficial ownership of, and all right, title and interest in, the option and the shares issuable upon exercise thereof.
Key Figures
Option grant size: 17,096 shares
Exercise price: $6.69/share
Expiration date: June 8, 2036
+2 more
5 metrics
Option grant size
17,096 shares
Underlying common stock for new stock option grant
Exercise price
$6.69/share
Conversion or exercise price of stock option
Expiration date
June 8, 2036
Stock option expiration
Vesting date
June 9, 2027
Earlier of this date or next Annual Meeting of Stockholders
Post-grant derivative holdings
17,096 options
Total derivative securities following transaction
Key Terms
Stock Option (Right to Buy), derivative security, beneficial ownership, Annual Meeting of Stockholders, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
derivative security financial
"transaction_type: "derivative" for the stock option grant"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
beneficial ownership financial
"Mr. Fleming disclaims beneficial ownership of, and all right, title and interest"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Annual Meeting of Stockholders financial
"earlier of June 9, 2027 and the date of the next Annual Meeting of Stockholders"
exercise price financial
"conversion_or_exercise_price of $6.6900 per underlying share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Harold Edward Fleming report in this Upstream Bio (UPB) Form 4?
Harold Edward Fleming reported receiving a stock option grant for 17,096 shares of Upstream Bio common stock. The option is compensation for his board service and represents a right to buy shares at a fixed exercise price in the future, subject to vesting.
What are the key terms of the Upstream Bio (UPB) stock option granted to Harold Edward Fleming?
The stock option covers 17,096 underlying common shares with a $6.69 exercise price and expires on June 8, 2036. It is a derivative security labeled as a “Stock Option (Right to Buy)” and was reported as a grant, award, or other acquisition.
When do Harold Edward Fleming’s Upstream Bio (UPB) options vest?
The options vest in full on the earlier of June 9, 2027 or the date of Upstream Bio’s next Annual Meeting of Stockholders. Vesting is conditioned on Mr. Fleming’s continued service as a director through the applicable vesting date, as described in the footnote.
Who ultimately benefits from the Upstream Bio (UPB) option grant reported by Harold Edward Fleming?
Although granted in Mr. Fleming’s name, he has agreed to receive and hold the securities for the benefit of Enavate Sciences, LP. He disclaims beneficial ownership and all right, title, and interest in the option and the shares issuable upon exercise.
How many Upstream Bio (UPB) derivative securities does the Form 4 show after this transaction?
After the reported grant, the Form 4 shows Mr. Fleming with 17,096 derivative securities in the form of stock options. These represent rights to acquire the same number of common shares at the stated exercise price, subject to vesting and expiration terms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
